Evidence map›Paper›PMID 31894446›Full record

ArticleBreast cancer research and treatment2020

Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.

Mara Tynan, Beth N Peshkin, Claudine Isaacs, Shawna Willey, Heiddis B Valdimarsdottir, Rachel Nusbaum, Gillian Hooker, Suzanne C O'Neill, Lina Jandorf, Scott P Kelly and 4 more

Open access · greenAbstract read
In one paragraph

Article in Breast cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Mara TynanGeorgetown Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA.
Beth N PeshkinGeorgetown Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA.
Claudine IsaacsGeorgetown Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA.
Shawna WilleyJess and Mildred Fisher Center for Hereditary Cancer and Clinical Genomics Research, Georgetown University, Washington, DC, USA.
Heiddis B ValdimarsdottirIcahn School of Medicine At Mount Sinai, Department of Population Health Science and Policy, Center for Behavioral Oncology, New York, NY, USA.
Rachel NusbaumSchool of Medicine, University of Maryland, Baltimore, MD, USA.
Gillian HookerConcert Genetics, Inc, Franklin, TN, USA.
Suzanne C O'NeillGeorgetown Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA.
Lina JandorfIcahn School of Medicine At Mount Sinai, Department of Population Health Science and Policy, Center for Behavioral Oncology, New York, NY, USA.
Scott P KellyAmerican Academy of Ophthalmology, San Francisco, CA, USA.
Jessica HeinzmannCarol G. Simon Cancer Center, Atlantic Health Systems, Summit, NJ, USA.
Sarah KelleherDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA.
Elizabeth PoggiGeorgetown Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA.
Marc D SchwartzGeorgetown Lombardi Comprehensive Cancer, Georgetown University, Washington, DC, USA. schwartm@georgetown.edu.ORCID http://orcid.org/0000-0002-2735-5413
Georgetown University · USAmerican Academy of Ophthalmology · USAtlantic Health System · USConcert Pharmaceuticals (United States) · USDuke Medical Center · USIcahn School of Medicine at Mount Sinai · USReykjavík University · ISUniversity of Maryland, Baltimore · US

Funding

Tissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5M
Decisions &Outcomes of BRCA1/2 Test for Breast PatientsR01CA074861 · NCI · GEORGETOWN UNIVERSITY · PI SCHWARTZ, MARC D · 1997 to 2008
$3.5M
NCI NIH HHS P30 CA051008NCI NIH HHS R01 CA074861NCI NIH HHS R01 CA74861
6 · The paper itself

Abstract

purposeRecent trends indicate increased use of contralateral prophylactic mastectomy (CPM) among newly diagnosed breast cancer patients, particularly those who test positive for a pathogenic variant in the BRCA1/2 genes. However, the rate of CPM among patients who test negative or choose not to be tested is surprisingly high. We aimed to identify patient predictors of CPM following breast cancer diagnosis among such patients.

methodsAs part of a randomized controlled trial of rapid genetic counseling and testing vs. usual care, breast cancer patients completed a baseline survey within 6 weeks of diagnosis and before definitive surgery. Analyses focused on patients who opted against testing (n = 136) or who received negative BRCA1/2 test results (n = 149). We used multivariable logistic regression to assess the associations between sociodemographic, clinical- and patient-reported factors with use of CPM.

resultsAmong patients who were untested or who received negative test results, having discussed CPM with one's surgeon at the time of diagnosis predicted subsequent CPM. Patients who were not candidates for breast-conserving surgery and those with higher levels of cancer-specific intrusive thoughts were also more likely to obtain a CPM.

conclusionThe strongest predictors of CPM in this population were objective clinical factors and discussion with providers. However, baseline psychosocial factors were also independently related to the receipt of CPM. Thus, although CPM decisions are largely guided by relevant clinical factors, it is important to attend to psychosocial factors when counseling newly diagnosed breast cancer patients about treatment options.

Indexed as

Prophylactic MastectomyAdultBreast NeoplasmsClinical Decision-MakingCombined Modality TherapyDisease ManagementFemaleGenes, BRCA1Genes, BRCA2Genetic CounselingGenetic Predisposition to DiseaseGenetic TestingHumansMiddle AgedMulticenter Studies as TopicNeoplasm StagingBreast cancerContralateral prophylactic mastectomyDecision makingGenetic testing

Identifiers

PMID31894446
PMCPMC7035174
OpenAlexW2998515851

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.